


The Journey of LUCASBIO Toward Advanced Regenerative Medicine



2019


07/ Founded



2020

07/ R&D Center Certification

10/ Venture Capital Approval




2023

02/ Approved for Mid-Risk Clinical Research in Advanced Regenerative Medicine: Autologous LB-DTK-COV19^b (No. R-2-0007)


04/ Selected for a Korea Health Industry Development Institute (KHIDI) research project on infectious disease prevention & treatment technology

04/ Selected for a Korea Fund for Regenerative Medicine (KFRM)-affiliated project on regenerative medicine-related technology development



2021


12/ Approved for Mid-Risk Clinical Research in Advanced Regenerative Medicine: Autologous CIK cells^a (No. R-2-0002)



2024


07/ Acquired GCLP Certification

09/ Approved for Clinical Trials by MFDS: Allogenic LB-DTK-COV19^c (No. 102261)



2026

01/ Approved for Clinical Trials by MFDS: Allogenic 1:1 LB-DTK-BKV^g (No. 109093)



2025

04/ Selected for a Research Project under the KHIDI Pediatric Disease Overcoming R&D Program

04/ Approved for Clinical Trials by MFDS: Allogenic LB-DTK-MV^d (No. 102599)

04/ Approved for High-Risk Clinical Research in Advanced Regenerative Medicine: Allogenic LB-DTK-MV^e (No. R-3-0017)

05/ Approved for Mid-Risk Clinical Research in Advanced Regenerative Medicine: Autologous LB-DTK-CMV^f (No. R-2-0020)




LUCASBIO, Specialized in Virus-Specific T-cell Immunotherapy

Platform 1. DTK

Direct Targeting Killer cell DTK


Antigen Learning and Expansion Process



Platform 2. CIK

Cytokine Induced Killer cell CIK

CIK Cell Activation and Differentiation Process



Clinical Trial Update

Platform	Disease	Cell Derived	R&D	Pre-Clinical	Phase 1	Phase 2	Phase 3	Product Approval
					Advanced Regenerative Medicine (ARM) Clinical Study			Treatment Approval
DTK	Lymphoma <i>after Autologous Hematopoietic Stem Cell Transplantation</i>	^a Autologous	Completed ARM Clinical Study					
	COVID-19 <i>Prolonged/Severe</i>	^b Autologous	Completed ARM Clinical Study					
		^c Allogenic	Ongoing Phase 1					
	Multi-Virus (MV) Infections (CMV, BKV, EBV) <i>after Allogeneic Hematopoietic Stem Cell Transplantation</i>	^d Allogenic	Ongoing Phase 1/2					
		^e Allogenic (1:1)	Ongoing ARM Clinical Study					
	CMV Retinitis <i>Refractory/Resistant to Antiviral Drugs</i>	^f Autologous	Ongoing ARM Clinical Study					
	BKV Hemorrhagic Cystitis <i>after Allogeneic Hematopoietic Stem Cell Transplantation</i>	^g Allogenic (1:1)	Approved for Phase 1/2					
	BKV Nephropathy <i>after Kidney Transplantation</i>	Autologous	Submitted ARM Plan					
	EBV-Associated Diseases	Autologous	In Preparation of ARM Plan					